These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

94 related items for PubMed ID: 15590188

  • 1. Effect of irradiation on neovascularization in rat skinfold chambers: implications for clinical trials of low-dose radiotherapy for wet-type age-related macular degeneration.
    Hori K, Saito S, Tamai M.
    Int J Radiat Oncol Biol Phys; 2004 Dec 01; 60(5):1564-71. PubMed ID: 15590188
    [Abstract] [Full Text] [Related]

  • 2. Treatment of age-related subfoveal neovascular membranes by teletherapy: results of a non-randomized study.
    Subaşi M, Akmansu M, Or M.
    Radiat Med; 1999 Dec 01; 17(2):169-73. PubMed ID: 10399787
    [Abstract] [Full Text] [Related]

  • 3. Long-term results after external radiotherapy in age-related macular degeneration. A prospective study.
    Prettenhofer U, Haas A, Mayer R, Stranzl H, Oechs A, Hackl A.
    Strahlenther Onkol; 2004 Feb 01; 180(2):91-5. PubMed ID: 14762661
    [Abstract] [Full Text] [Related]

  • 4. Overview of radiation trials for age-related macular degeneration.
    Kaiser PK.
    Retina; 2009 Jun 01; 29(6 Suppl):S34-5. PubMed ID: 19553797
    [Abstract] [Full Text] [Related]

  • 5. Twelve-month safety and visual acuity results from a feasibility study of intraocular, epiretinal radiation therapy for the treatment of subfoveal CNV secondary to AMD.
    Avila MP, Farah ME, Santos A, Kapran Z, Duprat JP, Woodward BW, Nau J.
    Retina; 2009 Feb 01; 29(2):157-69. PubMed ID: 19202425
    [Abstract] [Full Text] [Related]

  • 6. Proton beam irradiation for neovascular age-related macular degeneration.
    Zambarakji HJ, Lane AM, Ezra E, Gauthier D, Goitein M, Adams JA, Munzenrider JE, Miller JW, Gragoudas ES.
    Ophthalmology; 2006 Nov 01; 113(11):2012-9. PubMed ID: 16935343
    [Abstract] [Full Text] [Related]

  • 7. Photodynamic effects on retinal oxygen saturation, blood flow, and electrophysiological function in patients with neovascular age-related macular degeneration.
    Tsuchihashi T, Mori K, Peyman G, Shimada Y, Yoneya S.
    Retina; 2009 Nov 01; 29(10):1450-6. PubMed ID: 19816240
    [Abstract] [Full Text] [Related]

  • 8. External-beam radiation therapy for age-related macular degeneration: two years' follow-up results at a total dose of 20 Gy in 10 fractions.
    Churei H, Ohkubo K, Nakajo M, Hokotate H, Baba Y, Ideue J, Miyagawa K, Nakayama H, Hiraki Y, Kitasato T, Yabe N.
    Radiat Med; 2004 Nov 01; 22(6):398-404. PubMed ID: 15648455
    [Abstract] [Full Text] [Related]

  • 9. Macular microcirculation blood flow in patients with age related macular degeneration treated with photodynamic therapy and transpupillary thermotherapy.
    Kubicka-Trzaska A.
    Klin Oczna; 2007 Nov 01; 109(4-6):138-41. PubMed ID: 17725271
    [Abstract] [Full Text] [Related]

  • 10. Strontium plaque brachytherapy for exudative age-related macular degeneration: three-year results of a randomized study.
    Jaakkola A, Heikkonen J, Tommila P, Laatikainen L, Immonen I.
    Ophthalmology; 2005 Apr 01; 112(4):567-73. PubMed ID: 15808245
    [Abstract] [Full Text] [Related]

  • 11. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration.
    Rosenfeld PJ, Schwartz SD, Blumenkranz MS, Miller JW, Haller JA, Reimann JD, Greene WL, Shams N.
    Ophthalmology; 2005 Jun 01; 112(6):1048-53. PubMed ID: 15885778
    [Abstract] [Full Text] [Related]

  • 12. Prophylactic treatment of age-related macular degeneration report number 1: 810-nanometer laser to eyes with drusen. Unilaterally eligible patients.
    Friberg TR, Musch DC, Lim JI, Morse L, Freeman W, Sinclair S, PTAMD Study Group.
    Ophthalmology; 2006 Apr 01; 113(4):622.e1. PubMed ID: 16581422
    [Abstract] [Full Text] [Related]

  • 13. Characteristics of choroidal neovascularization in the complications of age-related macular degeneration prevention trial.
    Maguire MG, Alexander J, Fine SL, Complications of Age-related Macular Degeneration Prevention Trial (CAPT) Research Group.
    Ophthalmology; 2008 Sep 01; 115(9):1468-73, 1473.e1-2. PubMed ID: 18486222
    [Abstract] [Full Text] [Related]

  • 14. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
    Funk M, Karl D, Georgopoulos M, Benesch T, Sacu S, Polak K, Zlabinger GJ, Schmidt-Erfurth U.
    Ophthalmology; 2009 Dec 01; 116(12):2393-9. PubMed ID: 19815292
    [Abstract] [Full Text] [Related]

  • 15. Time course of morphologic effects on different retinal compartments after ranibizumab therapy in age-related macular degeneration.
    Ahlers C, Golbaz I, Stock G, Fous A, Kolar S, Pruente C, Schmidt-Erfurth U.
    Ophthalmology; 2008 Aug 01; 115(8):e39-46. PubMed ID: 18675694
    [Abstract] [Full Text] [Related]

  • 16. Regulation of subfoveal choroidal blood flow in age-related macular degeneration.
    Pournaras CJ, Logean E, Riva CE, Petrig BL, Chamot SR, Coscas G, Soubrane G.
    Invest Ophthalmol Vis Sci; 2006 Apr 01; 47(4):1581-6. PubMed ID: 16565395
    [Abstract] [Full Text] [Related]

  • 17. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study.
    Heier JS, Antoszyk AN, Pavan PR, Leff SR, Rosenfeld PJ, Ciulla TA, Dreyer RF, Gentile RC, Sy JP, Hantsbarger G, Shams N.
    Ophthalmology; 2006 Apr 01; 113(4):633.e1-4. PubMed ID: 16483659
    [Abstract] [Full Text] [Related]

  • 18. Pathology beyond neovascularization: new targets in age-related macular degeneration.
    Heier JS.
    Retina; 2009 Jun 01; 29(6 Suppl):S39-41. PubMed ID: 19553799
    [Abstract] [Full Text] [Related]

  • 19. Natural history of predominantly classic, minimally classic, and occult subgroups in exudative age-related macular degeneration.
    Shah AR, Del Priore LV.
    Ophthalmology; 2009 Oct 01; 116(10):1901-7. PubMed ID: 19592101
    [Abstract] [Full Text] [Related]

  • 20. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.
    Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, Puliafito CA, Davis JL, Flynn HW, Esquiabro M.
    Am J Ophthalmol; 2007 Apr 01; 143(4):566-83. PubMed ID: 17386270
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.